1226495-49-3 Usage
Uses
Used in Organic Synthesis:
1-Boc-3-(N-hydroxycarbamimidoyl)-pyrrolidine is used as a building block for the synthesis of various organic compounds. Its unique structure and functional groups allow for the creation of a wide range of molecules with diverse properties and applications.
Used in Medicinal Chemistry:
1-Boc-3-(N-hydroxycarbamimidoyl)-pyrrolidine is used as a starting material for the development of pharmaceutical compounds. Its hydroxycarbamimidoyl group offers the potential for interactions with biological targets, making it a valuable component in the design and synthesis of new drugs.
Used in Research and Development:
1-Boc-3-(N-hydroxycarbamimidoyl)-pyrrolidine is used as a research tool in both academic and industrial settings. Its versatility and potential applications in organic synthesis and medicinal chemistry make it an important compound for exploring new chemical reactions, developing novel compounds, and advancing our understanding of chemical and biological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1226495-49-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,6,4,9 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1226495-49:
(9*1)+(8*2)+(7*2)+(6*6)+(5*4)+(4*9)+(3*5)+(2*4)+(1*9)=163
163 % 10 = 3
So 1226495-49-3 is a valid CAS Registry Number.
1226495-49-3Relevant academic research and scientific papers
BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES
-
Page/Page column 44, (2010/05/14)
This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preve
BIARYL CARBOXAMIDES
-
Page/Page column 42-43, (2010/08/04)
This invention provides compounds of Formula (I) which are PAFR antagonists: Formula (I) and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.
